Exogenous progestagens and the human breast

Maturitas

Volumn 49, Issue 1, 2004, Pages 58-66

  Sitruk Ware, Regine ^a   Plu Bureau, Genevieve ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Breast cancer risk; Mammary cell differentiation; Menopausal therapy; Progestagens; Progestins

Indexed keywords

DEMEGESTONE; DESOGESTREL; ELCOMETRINE; ESTROGEN RECEPTOR; ETONOGESTREL; GESTAGEN; GESTODENE; NANDROLONE; NOMEGESTROL; NORELGESTROMIN; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; PROMEGESTONE; TRIMEGESTONE;

BENIGN TUMOR; BREAST CANCER; BREAST CELL; CANCER RISK; CELL PROLIFERATION; CELL STIMULATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; HORMONAL THERAPY; HORMONE ACTION; HORMONE BINDING; HUMAN; LONG TERM CARE; MOLECULAR DYNAMICS; NONHUMAN; PHARMACODYNAMICS; POSTMENOPAUSE; RISK REDUCTION;

ANIMALS; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MODELS, ANIMAL; PROGESTINS; RECEPTORS, PROGESTERONE;

EID: 4444286068     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.06.007     Document Type: Conference Paper

References (47)

1. Conneely O.M., Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 65:2000;571-577
2. Kenemans P., Bosman A. Breast cancer and postmenopausal hormone therapy. Best Pract. Res. Clin. Endocrinol. Metab. 17(1):2003;123-137
3. Thijssen J.H. Oestrogens, progestins and breast proliferation. Zentralblatt fur Gynekologie. 119:1997;43-47
4. Gompel A., Somai S., Chaouat M., et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. 65:2000;593-598
5. Isaksson E., Wang H., Sahlin B., von Schoultz B., Cline J.M., von Schoultz E. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A nd B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res. Treat. 79:2003;233-239
6. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks and benefits. Menopause. 9(1):2002;6-15
7. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas. 46(S1):2003;S7-S16
8. ®: a progestin with a unique pharmacological profile. Steroids. 65:2000;629-636
9. Catherino W.H., Jeng M.H., Jordan V.C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br. J. Cancer. 67:1993;945-952
10. Catherino W.H., Jordan V.C. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J. Steroid Biochem. Mol. Biol. 55(2):1995;239-246
11. Pasqualini J.R., Paris J., Sitruk-Ware R., et al. Progestins and breast cancer. J. Steroid Biochem. Mol. Biol. 65(1-6):1998;225-235
12. Druckmann R. Progestins and their effects on the breast. Maturitas. 46(S1):2003;S59-S69
13. Santen R., Pinkeron J., McCartney C., Petroni G.R. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. JCEM. 86:2001;16-23
14. Yen S.S.C., Martin P.L., Burnier A.M., et al. Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17β-estradiol in postmenopausal women. J. Clin. Endocrinol. Metab. 40:1975;518-521
15. Musgrove E.A., Lee C.S.L., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor, epidermal growth factor receptor, c-fos and c-myc genes. Mol. Cell Biol. 11:1991;5032-5043
16. Alkhalaf M., El-Mowafy A., Karam S. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. Eur. J. Cancer Prev. 11:2002;481-488
17. Laidlaw I.J., Clarke R.B., Howell A., Potten C.S., Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 136:1995;164-171
18. Clarke R.B., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression ans cell proliferation in the human breast. Cancer Res. 57:1997;4987-4989
19. Seeger H., Wallwiener D., Mueck A.O. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Horm. Metab. Res. 35(2):2003;76-80
20. Russo J., Hu Y.F., Silva I.D., Russo I.H. Cancer risk related to mammary gland structure and development. Microsc. Res. Tech. 52:2001;204-223
21. Russo J., Tay L.K., Russo I.H. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat. 2:1982;5-73
22. McMahon B., Cole P., Lin T.M., et al. Age at first birth and breast cancer risk. Bull. World Health Organ. 43:1970;209-221
23. McPherson K., Steel C.M., Dixon J.M. ABC of breast diseases. Breast cancer - epidemiology, risk factors, and genetics. Br. Med. J. 321:2000;624-628
24. Vogel P.M., Georgiade N.G., Fetter B.F., Vogel F.S., McCarty K.S. The correlation of histologic changes in the human breast with the menstrual cycle. Am. J. Pathol. 104(1):1981;23-34
25. Söderqvist G., Isaksson E., Von Schoulz B., et al. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 176:1997;123-128
26. Dobson R.R., Chan C.K., Knox F., Potten C.S., Bundred N.J. The effects of prolonged HT treatment in normal post-menopausal breast epithelium. BCRT. 64(1):2000;106. [abstract]
27. Miller N.A., Thomas M., Martin L.J. Feasibility of obtaining breast epithelial cells from healthy women for studies of cellular proliferation. Breast Cancer Res. Treat. 43:1997;201-210
28. Chang Lee T.T., Linares-Cruz G. Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell in vivo. Fertil. Steril. 63:1995;785-791
29. Foidart J.M., Colin C., Denoo X., et al. Estradiol and progesterone regulate the proliferaton of human breast epithelial cells. Fertil. Steril. 69(5):1998;963-969
30. Cline J.M., Soderqvist G., Von Shoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynolmogus macaques. Am. J. Obstet. Gynecol. 174:1996;93-100
31. Hofseth L.J., Raafat A.M., Osuch J.R., et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. JCEM. 84:1999;4559-4565
32. Suparto I.H., Williams J.K., Cline J.M., Anthony M.S., Fox J.L. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am. J. Obstet. Gynecol. 188:2003;1132-1140
33. Cline J.M., Soderqvist G., von Schoultz E., Skoog L., von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res. Treat. 48:1998;221-229
34. Plu-Bureau G., Lê M., Sitruk-Ware R., et al. Progestogen use and risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br. J. Cancer. 70:1994;270-277
35. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
36. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
37. Schairer C., Lubin J., Troisi R., et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Am. Med. Assoc. 283:2000;485-491
38. Magnusson C., Baron J.A., Correira N. Breast cancer risk following long term oestrogen and oestrogen-progestin replacement therapy. Int. J. Cancer. 31:1999;339-344
39. Ross R.K., Paganni-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332
40. Persson I., Weiderpass E., Bergkvist L. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Controls. 10:1999;253-260
41. De Lignières B., de Vathaire F., Fournier S., Urbinello R., Allaert F., Lê M.B. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 5:2002;332-340
42. Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27.
43. Speroff L. The million women study and breast cancer. Maturitas. 46:2003;1-6. [editorial]
44. Chlebowski R.T., Hendrix S.I., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. J. Am. Med. Assoc. 289:2003;3243-3253
45. Sitruk-Ware R (for the participants of the Round table). Progestins in hormonal therapy (HT): today, tomorrow and the next day: A round table discussion. Steroids 2003;68:973-9.
46. Anderson G.L., Limacher M., Assaf A.R. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. J. Am. Med. Assoc. 291(14):2004;1701- 1712
47. Luukkainen T. Issues to debate on the women's health initiative: failure of estrogen plus progestin therapy for prevention of breast cancer risk. Hum. Reprod. 18(8):2003;1559-1561